US2921883A - Novel coating material for medicaments - Google Patents
Novel coating material for medicaments Download PDFInfo
- Publication number
- US2921883A US2921883A US656750A US65675057A US2921883A US 2921883 A US2921883 A US 2921883A US 656750 A US656750 A US 656750A US 65675057 A US65675057 A US 65675057A US 2921883 A US2921883 A US 2921883A
- Authority
- US
- United States
- Prior art keywords
- pellets
- fatty
- carbon atoms
- alcohol
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Definitions
- This invention relates to a new coating material useful for prolonging the release of a medicament upon oral ad ministration and medicaments coated with said material.
- the coating material of this invention is useful for coating medicaments using any of the conventional coat ing techniques.
- it can be used to coat medicament pellets employing a coating pantechnique; it can be used to form a pellet of the coating material with the medicament dispersed therein; or a dispersion of medicament in the coating material can be spray dried to coat the medicament.
- Th coating of small medicament-containing pellets with a fatty material or a fatty material admixed with a waxy material in order to obtain pellets with a size of the order from 0.1 to 2.0 mm. in diameter is known to the art. These pellets are encapsulated and administered to humans to provide for sustained release of the medicament over a long period of time, from about eight to ten hours.
- coating material of this invention enables a continuous application of the coating material to the pellets to be employed during the manufacturing process, a great advantage over the multi-coating procedures of the prior art.
- the coating material of this invention comprises an intimate mixture of a nontoxic, solid hydroxylated lipid material and a nontoxic, solid cellulose derivative.
- lipid material are fatty alcohols having from 12 to 31 carbon atoms, such as for instance lZ-hydroxystearyl alcohol, lO-hydroxystearyl alcohol, 9,10-dihydroxystearyl alcohol, 14-hydroxybehenyl alcohol, lauryl alcohol, ceryl alcohol, carnubyl alcohol, stearyl aoohol, myricyl alcohol, behenyl alcohol, cetyl alcohol, myristyl alcohol or arachyl alcohol; fatty mono, di or triesters of glycols and glycerols which have at least one free hydroxy group and are derived from fatty acids of from 12 to 22 carbons, such as glyceryl distearate, glyceryl monostearate, propylene glycol monolaurate, ethylene glycol monopalmitate, ethylene glycol mono-lZ-hydroxystea
- Solid esters of either fatty hydroxy acids with lower aliphatic alcohols or fatty polyhydric alcohols with lower aliphatic acids, the said esters having a total carbon content of from 12 to 62 carbon atoms are also of value in this combination.
- Exemplary of such compounds are propyl 9,10-dihydroxystearate, dodecyl 9,10-dihydroxystearate, IZ-hydroxystearyl butyrate, IZ-hydroxystearyl palmitate, octadecyl 9,10-dihydroxystearate', propyl 13,14- dihydroxybehenate, or octadecyl 12-hydroxylaurate.
- Advantageous compounds are glyceryl tri-l2-hydroxy stearate, glyceryl di-lZ-hydroxystearate, glyceryl mono- IZ-hydroxystearate, behenyl alcohol, stcaryl alcohol and l2-hydroxystearyl alcohol.
- a preferred substance is hydrogenated castor oil whose major component is glycryl tri-lZ-hydroxystearate.
- Exemplary of the cellulose derivative of the combination of this invention are cellulosic ethers, such as ethyl cellulose, methyl cellulose, propyl cellulose; cellulosic esters, such as cellulose acetate, cellulose acetate butyrate, cellulose propionate, cellulose caprate, cellulose acetate propionate or cellulose acetate stearate.
- cellulosic ethers such as ethyl cellulose, methyl cellulose, propyl cellulose
- cellulosic esters such as cellulose acetate, cellulose acetate butyrate, cellulose propionate, cellulose caprate, cellulose acetate propionate or cellulose acetate stearate.
- the cellulose derivatives preferably are those in which the R moiety of cellulose-R is either an aliphatic acyl of 2 to 22 carbons'or an aliphatic alkyl of from 1 to 5 carbons.
- the water insoluble cellulose derivatives are of particular advantage.
- Advantageous and preferred cellulosic derivatives are ethyl cellulose and cellulose acetate butyrate.
- the components of the coating material are mixed either by melting the constituents together with intimate mixing or preferably by dissolving the constituents in an organic solvent in which they are sufiiciently soluble, such as carbon tetrachloride, ethylene dichloride, chloroform, ethyl acetate or benzene, then evaporating the solvent.
- T he ratio by weight of lipid material to cellulosic material may be varied widely, such as from 1:1 to 20:1. Preferably, proportions about 1:1 to about 9:1 are used.
- a particularly useful combination is hydrogenated castor oil of which the major constituent is glyceryl tri-12-hydroxystearate and ethyl cellulose preferably in proportions of about 4:1.
- the coating material can be dissolved, usually in about 10% solution, in a suitable organic solvent, such as chloroform or alcohol-chloroform mixture and gradually applied by continuous spraying or vaporizing to the medicament-containing pellets which are agitated as the coating material is applied, such as in a coating pan.
- a suitable organic solvent such as chloroform or alcohol-chloroform mixture
- the pellets are then dried.
- the coating material can be applied in successive coats by alternately spraying or vaporizing to the pellets and drying until the de sired number of coats have been applied. It is preferred to have the coating a minimum of 2% by weight of the coated pellets.
- the coating will be 5% to 15% by weight of the coated pellets.
- the medicament which is coated with the coating material of this invention in a finely divided form, for example, about 500 microns (U.S. 35 mesh) or smaller in size
- the medicament in comminuted form mesh (U.S.) or smaller] is suspended in a volatile solution of the coating material, for example, the coating material in an organic solvent such as chloroform.
- the thus formed suspension is then spray dried to form dry treated particles substantially coated with the coating material.
- This spray drying may be carried out in apparatus conventionally used for spray drying and-which is well known tothe art.
- the spray drying conditions may vary. within wide ranges. however, preferred to use an inlet temperature of the spraying chamber of not more than about 150 C. and an outlet temperature of the spraying chamber of not less than about 50 C.
- the spray dried material may be used as such or, if desired, can be compressed into a. tablet.
- the coating material of this invention can be employed to provide for a sustained release of medicament by molding pellets using a dispersion of the selected medicament in a melt of the coating material of this invention, this admixture being formed in suitable molds.
- the sustained release coating of this invention provides satisfactory sustained release rates of medicament in the gastrointestinal tract. It will be understood that this susained release of medicament over a period of many hours differs from the result achieved with enteric coatings which protect the medicament during passage through the stomach and then releases all of the medicament at substantially one time.
- the sustained released rates are maintained well upon aging. Since the coatings are not very pH sensitive, the medicament release is not affected by the emptying time of the stomach and the varying pl-l caused thereby. Further, the coatings of this invention are harder than the previously used glyceryl stearate-wax mixtures. For this reason the coated pellets are less liable to distortion in the coating pans as Well as more resistant to injury by shock during subsequent commercial handling. In addition the coatings of this invention are less subject to cracking caused by extreme temperature changes, such as from near zero conditions often encountered while shipping to the room temperature conditions of storage.
- compositions having a medicament coated with the coating material of this invention give good sustained release of medicament with a thinner coat than is possible with the prior art combinations. This is reflected in shorter operating times on each batch of pellets, thereby saving man and machine power as well as coating material.
- Example I pan is set in rotation and one-third of the alkaloid coating solution is added by slowly pouring it onto the pellets in order to wet them evenly. Then 400 gm. of coating powder, containing equal parts of starch and sugar, are sprinkled on the wetted mass of nonpareil seeds. The pellets are dried in warm air. The addition of the alka- 'loid solution, starch-sugar coating powder and the drying procedure are repeated to apply two additional coats. Two final coatings are added, each coat consisting of 350 ml. of syrup U.S.P. The pellets are thoroughly dried It is, I
- the screened pellets are returned to a coating pan and coated with a fat-cellulosic coating solution made by admixing l000 gm. of hydrogenated castor oil, 250 gm. of ethyl cellulose and sufiicient chloroform to make 12.5 liters. Ten liters of the solution are applied in a continuous manner at room temperature. After applying the cellulose solution. After applying the solution, the pellets are dried with air and two-thirds of the remaining batch removed.
- a fat-cellulosic coating solution made by admixing l000 gm. of hydrogenated castor oil, 250 gm. of ethyl cellulose and sufiicient chloroform to make 12.5 liters.
- Ten liters of the solution are applied in a continuous manner at room temperature. After applying the cellulose solution. After applying the solution, the pellets are dried with air and two-thirds of the remaining batch removed.
- the remainder of the batch, containing one-fourth of the original pellets, is further coated with 1.0 l. of fatcellulose solution. After applying the solution, the pellets are dried with air.
- the three groups of pellets thus formed are placed in a single container and thoroughly mixed to provide a uniform mixture. Size No. 4 gelatin capsules are then filled with the thus mixed pellets to provide a total dosage of 0.4 mg. of mixed alkaloids per capsule. Each capsule contains about 350 pellets.
- Each No. 4 capsule provides the desired body level of belladonna alkaloids in about one-half hour.
- the coated pellets continue to provide sufficient belladonna alkaloids to maintain this desired body level for approximately ten hours.
- Example ll Pellets coated "with belladonna alkaloids and overcoated with syrup are prepared and screened as in Example I.
- the screened pellets approximately 20 kg., are returned to a coating pan and coated with 12 l. of a fat-cellulosic coating solution made by admixing 1000 gm. of hydrogenated castor oil, 250 gm. of ethyl cellulose and sufficient chloroform to make 12.5 liters.
- the coating solution is applied gradually and con tinuously until the coating operation is completed.
- the pellets are dried with air and screened through a #16 mesh screen and on a #25 mesh screen.
- the pellets are thoroughly mixed and filled into size No. 4 gelatin capsules to provide a total dosage of 0.4 mg. of mixed alkaloids per capsule.
- Each capsule contains about 350 pellets.
- Each No. 4 capsule provides the desired body level of belladonna alkaloids in about one-half hour.
- the coated pellets continue to maintain this desired body level for approximately ten hours.
- Example Ill Nonpareil seeds (sugar pellets), 18.3 kg., like those used in Example I are placed in a 36-inch coating pan.
- a coating solution is prepared by dissolving 1.2 kg. of chlorprophenpyridamine maleate in 2.3 l. of 10% gelatin solution; The pan is set in rotation and approximately ml. of the coating solution is added by slowly pouring over the pellets to evenly wet them. The pellets are dried in warm air. The addition of the coating solution and the drying procedure are repeated until the solution is exhausted. When all of the coating solution has been applied, two final coats consisting of 150 ml. syrup U.S.P. are applied. The pellets are thoroughly dried and screened through a #16 mesh screen and a #25 mesh screen. The yield is approximately 20 kg.
- the screened pellets are returned to a coating pan and coated with the fat-cellulosic coating solution as in Example I.
- the three groups of pellets thus formed are placed in a single container and thoroughly mixed to provide a uniform mixture.
- Each No. 3 capsule provides the desired body level of chlorprophenpyridamine maleate in about one-half sule. contains about .450 pellets.
- Example IV A Pellets coated with chlorprophenpyridamine maleate and overcoated with syrup are prepared and screened as in Example III. The yield is 20 kg.
- Eighteen kilograms of the screened pellets are returned to a coating pan and coated with 10.8 1. of a fat-cellulosic coating solution made by admixing 1000 gm. of hydrogenated castor oil, 250 gm. of ethyl cellulose and sufiicient chloroform to make 12.5 liters.
- the coating solution is applied gradually and continuously until the coating operation is completed.
- the pellets are dried with air and screened through a #16 mesh screen and on a #25 mesh screen.
- the remaining 2 kg. of the originally produced pellets overcoated with syrup are screened through a #16 mesh screen and on a #25 mesh screen.
- the fat-cellulosic coated pellets are then thoroughly mixed with the pellets which are not fat-cellulosic coated in a ratio of 9:1 to provide a uniform mixture.
- Size No. 3 gelatin capsules are filled with the thus mixed pellets to provide a total dosage of 8 mg. of chlorprophenpyridamine maleate per capsule.
- Each cap- Each No. 3 capsule provides the desired body level of chlorprophenpyridamine maleate in about one-half hour.
- the coated pellets continue to provide suflicieut chlorprophenpyridamine maleate to maintain this desired body level for approximately ten hours.
- Example VII Percent w./v. Hydrogenated castor oil 9 Ethyl cellulose (15 cps.) 1 Chloroform, q.s. 100% volume.
- Example VIII Percent w./v. Glyceryl distearate 8 Ethyl cellulose (50 cps) 2 Ethyl alcohol, q.s. 100% volume.
- Example XIII Percent w./v. Glyceryl distearate 12 Cellulose acetate butyrate 3 Ethyl alcohol, q.s. 100% volume.
- Example XIV Percent w./v. Behenyl alcohol 5 Cellulose acetate butyrate 5 Ethyl alcohol: chloroform (3:1), q.s. 100% volume.
- Example XVI Percent w./v. IZ-hydroxystearyl alcohol 5 Cellulose acetate butyrate S Ethyl alcohol: chloroform (3:1), q.s. 100% volume.
- a coating material for medicamentsto prolong the release of the medicament in the gastrointestinal tract which comprises an intimate mixture of a non-toxic, solid hydroxylated lipid material selected from the group consisting of a fatty alcohol having from 12 to 31 carbon atoms; a fatty ester of a glycol which has at least one free hydroxy group with a fatty acid of from 12 to 22 carbon atoms; a fatty ester of a glycerol which has at least one free hydroxy group with a fatty acid of from 12 to 22 carbon atoms; a solid ester of a fatty hydroxy acid with a lower aliphatic alcohol, the said ester having a total carbon content of 12 to 62 carbon atoms; a solid ester of a fatty polyhydric alcohol with a lower aliphatic acid, the said ester having a total carbon content of 12 to 62 carbon atoms; and a non-toxic, solid cellulose derivative represented by cellulose-R in which the R moiety is a member selected from
- a coating material in accordance with claim 1 characterized in that the ratio by weight of said lipid ma terial to said cellulosic material is about 4: 1.
- a coating material for medicaments to prolong the release of the medicament in the gastrointestinal tract which comprises an intimate mixture of hydrogenated castor oil and ethyl cellulose, the ratio by weight of hydrogenated castor oil to ethyl cellulose being from about 1:1 to about 9:1.
- a coating material in accordance with claim 3 characterized in that the ratio by weight of hydrogenated castor oil to ethyl cellulose is about 4: 1.
- a coating material for medicaments to prolong the release of the medicament in the gastrointestinal tract which comprises an intimate mixture of hydrogenated 5 characterized in that'the ratio .by weight of IZ-hydroxy- 'stearyl'alcohol to ethyl cellulose is about 4:1.
- castor oil and cellulose acetate butyrate the ratio by weight. of hydrogenated castor oil to cellulose acetate butyrate being from about 1: 1 to about 9: 1.
- a coating material in accordance with claim 5 characterized in that the ratio by weight of hydrogenated castor oil to cellulose acetate butyrate is about 4:1.
- a coating material for medicaments to prolong the release of the medicament in the gastrointestinal tract which comprises an intimate mixture of 12 hydroxystearyl alcohol and ethyl cellulose, the ratio by weight of IZ-hydroxystearyl alcohol to ethyl cellulose being from about 1:1 to about 9:1.
- a coating material in accordance with claim 7 which comprises an intimate mixture of l2-hydroxystearyl alcohol and cellulose acetate butyrate, the ratio by weight of IZ-hydroxystearyl alcohol to cellulose acetate butyrate being from about 1:1 to about 9:1.
- a coating material in accordance with claim 9 characterized in that the ratio by weight of l2-hydroxystearyl alcohol to cellulose acetate butyrate is about 4:1.
- a coating material for medicaments to prolong the release of the medicament in the gastrointestinal tract which comprises an intimate mixture of glyceryl tri-12- hydroxystearate and ethyl cellulose, the ratio by weight of glyceryl tri-lZ-hydroxystearate to ethyl cellulose being from about 1:1 to about 9:1.
- a coating material in accordance with claim 11 characterized in that the ratio by weight of glyceryl tri- 12-hydroxystearate to ethyl cellulose is about 4: 1.
- a pharmaceutical preparation providing a prolonged release of the contained medicament in the gastrointestinal tract which comprises a medicament protected by a coating comprising an intimate mixture of a nontoxic, solid hydroxylated lipid material selected from the group consisting of glyceryl tri-IZ-hydroxystearate, glyceryl di-12-hydroxystearate, glyceryl mono-IZ-hydroxystearate, behenyl alcohol, stearyl alcohol and 12-hydroxystearyl alcohol and a non-toxic, solid cellulose derivative selected from the group consisting of ethyl cellulose, methyl cellulose, propyl cellulose, cellulose acetate, cellulose acetate butyrate, cellulose propionate, cellulose caprate, cellulose acetate propionate and cellulose acetate stearate, the ratio by weight of said lipid material to said cellulosic material being from about 1:1 to about 9: 1.
- a pharmaceutical preparation in accordance with claim 13 characterized in that the ratio by weight of said lipid material to said cellulosic material is about 4:1.
Description
United States Patent 2,921,883 Patented Jan. 19, 1960 NOVEL COATING MATERIAL FOR MEDICAlVIENTS N Drawing. Application May 3, 1957 Serial No. 656,750
14 Claims. (Cl. 167-82) and Joseph V. Swin- Pa., assignors to Smith, Kline 8: Philadelphia, Pa., a corporation This invention relates to a new coating material useful for prolonging the release of a medicament upon oral ad ministration and medicaments coated with said material.
The coating material of this invention is useful for coating medicaments using any of the conventional coat ing techniques. For example, it can be used to coat medicament pellets employing a coating pantechnique; it can be used to form a pellet of the coating material with the medicament dispersed therein; or a dispersion of medicament in the coating material can be spray dried to coat the medicament.
Th coating of small medicament-containing pellets with a fatty material or a fatty material admixed with a waxy material in order to obtain pellets with a size of the order from 0.1 to 2.0 mm. in diameter is known to the art. These pellets are encapsulated and administered to humans to provide for sustained release of the medicament over a long period of time, from about eight to ten hours.
, The manufacture of such coated pellets has been complicated by the small size of the pellets and the critical nature of the thickness of the coating in order to obtain a proper release of medicament. Complicating the picture further was the fact that the previous coating materials, for instance glyceryl monostearate and beeswax, due to solid state changes of the coatings, such as microcrystallization, i.e. changes of one crystalline form to another, teuded to alter the release of the medicament over a period of time, such as slowing down the medicament release. Therefore, in order to solve this problem and obtain products with reliable sustained release characteristics, complicated aging and blending techniques had to be employed. It is an object of this invention to provide a coating material which eliminates these problems.
Further, use of the coating material of this invention enables a continuous application of the coating material to the pellets to be employed during the manufacturing process, a great advantage over the multi-coating procedures of the prior art.
The coating material of this invention comprises an intimate mixture of a nontoxic, solid hydroxylated lipid material and a nontoxic, solid cellulose derivative. Exemplary of the lipid material are fatty alcohols having from 12 to 31 carbon atoms, such as for instance lZ-hydroxystearyl alcohol, lO-hydroxystearyl alcohol, 9,10-dihydroxystearyl alcohol, 14-hydroxybehenyl alcohol, lauryl alcohol, ceryl alcohol, carnubyl alcohol, stearyl aoohol, myricyl alcohol, behenyl alcohol, cetyl alcohol, myristyl alcohol or arachyl alcohol; fatty mono, di or triesters of glycols and glycerols which have at least one free hydroxy group and are derived from fatty acids of from 12 to 22 carbons, such as glyceryl distearate, glyceryl monostearate, propylene glycol monolaurate, ethylene glycol monopalmitate, ethylene glycol mono-lZ-hydroxystearate glyceryl monobehenate, glyceryl monocaprate, glyceryl didecanoate, propylene glycol monomyristate, glyceryl monol Z-hydroxystearate, glyceryl tri-12-hydroxystearate,
propylene di-IZ-hydroxystearate, ethylene glycol di-9,10-
dihydroxystearate, glyceryl tri-dihydroxystearate, glyceryl mono-12-hydroxystearate, glyceryl di-12-hydroxystearate, glyceryl di-ll-hydroxypalmitate, glyceryl mono-l6-hydroxystearate, glyceryl tri-lZ-hydroxylaurate, glyceryl trialeurate or glyceryl monostearate di-lZ-hydroxystearate.
Solid esters of either fatty hydroxy acids with lower aliphatic alcohols or fatty polyhydric alcohols with lower aliphatic acids, the said esters having a total carbon content of from 12 to 62 carbon atoms are also of value in this combination. Exemplary of such compounds are propyl 9,10-dihydroxystearate, dodecyl 9,10-dihydroxystearate, IZ-hydroxystearyl butyrate, IZ-hydroxystearyl palmitate, octadecyl 9,10-dihydroxystearate', propyl 13,14- dihydroxybehenate, or octadecyl 12-hydroxylaurate.
Advantageous compounds are glyceryl tri-l2-hydroxy stearate, glyceryl di-lZ-hydroxystearate, glyceryl mono- IZ-hydroxystearate, behenyl alcohol, stcaryl alcohol and l2-hydroxystearyl alcohol. A preferred substance is hydrogenated castor oil whose major component is glycryl tri-lZ-hydroxystearate.
Exemplary of the cellulose derivative of the combination of this invention are cellulosic ethers, such as ethyl cellulose, methyl cellulose, propyl cellulose; cellulosic esters, such as cellulose acetate, cellulose acetate butyrate, cellulose propionate, cellulose caprate, cellulose acetate propionate or cellulose acetate stearate.
The cellulose derivatives preferably are those in which the R moiety of cellulose-R is either an aliphatic acyl of 2 to 22 carbons'or an aliphatic alkyl of from 1 to 5 carbons.
The water insoluble cellulose derivatives are of particular advantage. Advantageous and preferred cellulosic derivatives are ethyl cellulose and cellulose acetate butyrate.
The components of the coating material are mixed either by melting the constituents together with intimate mixing or preferably by dissolving the constituents in an organic solvent in which they are sufiiciently soluble, such as carbon tetrachloride, ethylene dichloride, chloroform, ethyl acetate or benzene, then evaporating the solvent. T he ratio by weight of lipid material to cellulosic material may be varied widely, such as from 1:1 to 20:1. Preferably, proportions about 1:1 to about 9:1 are used. A particularly useful combination is hydrogenated castor oil of which the major constituent is glyceryl tri-12-hydroxystearate and ethyl cellulose preferably in proportions of about 4:1.
The coating material can be dissolved, usually in about 10% solution, in a suitable organic solvent, such as chloroform or alcohol-chloroform mixture and gradually applied by continuous spraying or vaporizing to the medicament-containing pellets which are agitated as the coating material is applied, such as in a coating pan. The pellets are then dried. If desired, the coating material can be applied in successive coats by alternately spraying or vaporizing to the pellets and drying until the de sired number of coats have been applied. It is preferred to have the coating a minimum of 2% by weight of the coated pellets. Advantageously the coating will be 5% to 15% by weight of the coated pellets.
Where it is desirable to have the medicament which is coated with the coating material of this invention in a finely divided form, for example, about 500 microns (U.S. 35 mesh) or smaller in size, the medicament in comminuted form mesh (U.S.) or smaller] is suspended in a volatile solution of the coating material, for example, the coating material in an organic solvent such as chloroform. The thus formed suspension is then spray dried to form dry treated particles substantially coated with the coating material. This spray drying may be carried out in apparatus conventionally used for spray drying and-which is well known tothe art. The spray drying conditions may vary. within wide ranges. however, preferred to use an inlet temperature of the spraying chamber of not more than about 150 C. and an outlet temperature of the spraying chamber of not less than about 50 C. The spray dried material may be used as such or, if desired, can be compressed into a. tablet.
Similarly, the coating material of this invention can be employed to provide for a sustained release of medicament by molding pellets using a dispersion of the selected medicament in a melt of the coating material of this invention, this admixture being formed in suitable molds.
The sustained release coating of this invention provides satisfactory sustained release rates of medicament in the gastrointestinal tract. It will be understood that this susained release of medicament over a period of many hours differs from the result achieved with enteric coatings which protect the medicament during passage through the stomach and then releases all of the medicament at substantially one time.
Further the sustained released rates are maintained well upon aging. Since the coatings are not very pH sensitive, the medicament release is not affected by the emptying time of the stomach and the varying pl-l caused thereby. Further, the coatings of this invention are harder than the previously used glyceryl stearate-wax mixtures. For this reason the coated pellets are less liable to distortion in the coating pans as Well as more resistant to injury by shock during subsequent commercial handling. In addition the coatings of this invention are less subject to cracking caused by extreme temperature changes, such as from near zero conditions often encountered while shipping to the room temperature conditions of storage.
Pharmaceutical preparations having a medicament coated with the coating material of this invention give good sustained release of medicament with a thinner coat than is possible with the prior art combinations. This is reflected in shorter operating times on each batch of pellets, thereby saving man and machine power as well as coating material.
The variations possible in utilizing the coating combination of this invention will be more apparent from consideration of the following examples:
Example I pan is set in rotation and one-third of the alkaloid coating solution is added by slowly pouring it onto the pellets in order to wet them evenly. Then 400 gm. of coating powder, containing equal parts of starch and sugar, are sprinkled on the wetted mass of nonpareil seeds. The pellets are dried in warm air. The addition of the alka- 'loid solution, starch-sugar coating powder and the drying procedure are repeated to apply two additional coats. Two final coatings are added, each coat consisting of 350 ml. of syrup U.S.P. The pellets are thoroughly dried It is, I
The remainder ofthe batch, containing three-fourths of the coated pellets, further is coated with 1.5 1. of fat and screened through a #16 mesh screen and on a #25 V mesh screen. The yield is approximately 20 kg.
The screened pellets are returned to a coating pan and coated with a fat-cellulosic coating solution made by admixing l000 gm. of hydrogenated castor oil, 250 gm. of ethyl cellulose and sufiicient chloroform to make 12.5 liters. Ten liters of the solution are applied in a continuous manner at room temperature. After applying the cellulose solution. After applying the solution, the pellets are dried with air and two-thirds of the remaining batch removed.
The remainder of the batch, containing one-fourth of the original pellets, is further coated with 1.0 l. of fatcellulose solution. After applying the solution, the pellets are dried with air.
The three groups of pellets thus formed are placed in a single container and thoroughly mixed to provide a uniform mixture. Size No. 4 gelatin capsules are then filled with the thus mixed pellets to provide a total dosage of 0.4 mg. of mixed alkaloids per capsule. Each capsule contains about 350 pellets.
Each No. 4 capsule provides the desired body level of belladonna alkaloids in about one-half hour. The coated pellets continue to provide sufficient belladonna alkaloids to maintain this desired body level for approximately ten hours.
Example ll Pellets coated "with belladonna alkaloids and overcoated with syrup are prepared and screened as in Example I. The screened pellets, approximately 20 kg., are returned to a coating pan and coated with 12 l. of a fat-cellulosic coating solution made by admixing 1000 gm. of hydrogenated castor oil, 250 gm. of ethyl cellulose and sufficient chloroform to make 12.5 liters.
The coating solution is applied gradually and con tinuously until the coating operation is completed. The pellets are dried with air and screened through a #16 mesh screen and on a #25 mesh screen. The pellets are thoroughly mixed and filled into size No. 4 gelatin capsules to provide a total dosage of 0.4 mg. of mixed alkaloids per capsule. Each capsule contains about 350 pellets. Each No. 4 capsule provides the desired body level of belladonna alkaloids in about one-half hour. The coated pellets continue to maintain this desired body level for approximately ten hours.
- Example Ill Nonpareil seeds (sugar pellets), 18.3 kg., like those used in Example I are placed in a 36-inch coating pan. A coating solution is prepared by dissolving 1.2 kg. of chlorprophenpyridamine maleate in 2.3 l. of 10% gelatin solution; The pan is set in rotation and approximately ml. of the coating solution is added by slowly pouring over the pellets to evenly wet them. The pellets are dried in warm air. The addition of the coating solution and the drying procedure are repeated until the solution is exhausted. When all of the coating solution has been applied, two final coats consisting of 150 ml. syrup U.S.P. are applied. The pellets are thoroughly dried and screened through a #16 mesh screen and a #25 mesh screen. The yield is approximately 20 kg.
The screened pellets are returned to a coating pan and coated with the fat-cellulosic coating solution as in Example I.
The three groups of pellets thus formed are placed in a single container and thoroughly mixed to provide a uniform mixture.
Size No. 3 gelatin capsules are then filled with the thus mixed pellets to provide a total dosage of 8 mg. of chlorprophenpyridamine maleate per capsule. Each capsule contains about 450 pellets.
Each No. 3 capsule provides the desired body level of chlorprophenpyridamine maleate in about one-half sule. contains about .450 pellets.
I Example IV I A Pellets coated with chlorprophenpyridamine maleate and overcoated with syrup are prepared and screened as in Example III. The yield is 20 kg.
Eighteen kilograms of the screened pellets are returned to a coating pan and coated with 10.8 1. of a fat-cellulosic coating solution made by admixing 1000 gm. of hydrogenated castor oil, 250 gm. of ethyl cellulose and sufiicient chloroform to make 12.5 liters. The coating solution is applied gradually and continuously until the coating operation is completed. The pellets are dried with air and screened through a #16 mesh screen and on a #25 mesh screen.
The remaining 2 kg. of the originally produced pellets overcoated with syrup are screened through a #16 mesh screen and on a #25 mesh screen. The fat-cellulosic coated pellets are then thoroughly mixed with the pellets which are not fat-cellulosic coated in a ratio of 9:1 to provide a uniform mixture.
Size No. 3 gelatin capsules are filled with the thus mixed pellets to provide a total dosage of 8 mg. of chlorprophenpyridamine maleate per capsule. Each cap- Each No. 3 capsule provides the desired body level of chlorprophenpyridamine maleate in about one-half hour. The coated pellets continue to provide suflicieut chlorprophenpyridamine maleate to maintain this desired body level for approximately ten hours.
Example V Percent w./v. Hydrogenated castor oil 8 Ethyl cellulose (15 cps.) 2
Chloroform, q.s. 100% volume.
The above solution is applied to medicated sugar pellets at room temperature, following the procedure of Example I, to a 6% increase in weight of the pellets. These pellets are filled directly into gelatin capsules with Chloroform, q.s. 100% volume.
The above solution is applied to medicated sugar pellets at room temperature, following the procedure of Example I, to a 6% increase in Weight of the pellets.
Example VII Percent w./v. Hydrogenated castor oil 9 Ethyl cellulose (15 cps.) 1 Chloroform, q.s. 100% volume.
The above solution is applied to medicated sugar pellets at room temperature, following the procedure of EX- ample I, to a 6% increase in weight of the pellets.
Example VIII Percent w./v. Glyceryl distearate 8 Ethyl cellulose (50 cps) 2 Ethyl alcohol, q.s. 100% volume.
This solution is applied to medicated sugar pellets at 60 C., following the procedure of Example I, to an 8% increase in weight of the pellets.
Example IX Percent w./v. Glyceryl tri-12-hydroxystearate 4 Glyceryl distearate 4 Ethyl cellulose (15 cps.) 2
Ethyl alcohol, q.s. 100% volume.
The above. solution is applied to medicated sugar pellets, at' 60 0., following. the procedure of Example II, to a increase in weight of the pellets.
The above solution is applied to medicated sugar pellets at' 60 C., following the procedure of Example I, to a 10% increase in weight of the pellets.
Example XI Percent w./v. Hydrogenated castor oil 12 Cellulose acetate butyrate 3 Chloroform, q.s. 100% volume.
The above solution is applied to medicated sugar pellets at room temperature, following the procedure of Example I, to a 6% increase in weight of the pellets.
Example XII Percent w./v. Hydrogenated castor oil 6.7 Cellulose acetate butyrate 3.3 Chloroform, q.s. 100% volume.
The above solution is applied to medicated sugar pellets at room temperature, following the procedure of EX- ample I, to a 6% increase in weight of the pellets.
Example XIII Percent w./v. Glyceryl distearate 12 Cellulose acetate butyrate 3 Ethyl alcohol, q.s. 100% volume.
The above solution is applied to medicated sugar pellets at 60 0., following the procedure of Example 11, to
a 10% increase in weight of the pellets.
Example XIV Percent w./v. Behenyl alcohol 5 Cellulose acetate butyrate 5 Ethyl alcohol: chloroform (3:1), q.s. 100% volume.
The above solution is applied to medicated sugar pellets at room temperature, following the procedure of Example I, to a 7% increase in weight of the pellets.
Example XV Percent w./v. Stearyl alcohol 5 Cellulose acetate butyrate 5 Ethyl alcohol: chloroform (3:1), q.s. 100% volume.
The above solution is applied to medicated sugar pellets at room temperature, following the procedure of Example I to a 9% increase in weight of the pellets.
Example XVI Percent w./v. IZ-hydroxystearyl alcohol 5 Cellulose acetate butyrate S Ethyl alcohol: chloroform (3:1), q.s. 100% volume.
The above solution is applied to medicated sugar pellets at room temperature, following the procedure of Example I, to a 9% increase in weight of the pellets.
Example XVII Percent w./v. Hydrogenated castor oil 5.6 Ethylene glycol monohydroxystearate 2.4 Cellulose acetate butyrate 2.0
7 Chloroform, q.s. volume.
The above solution is applied to medicated sugar pellets at :room: temperature, following the. procedure "oil Example II, to a 9% increase in weight of the pellets.
What is claimed is:
I l. A coating material for medicamentsto prolong the release of the medicament in the gastrointestinal tract which comprises an intimate mixture of a non-toxic, solid hydroxylated lipid material selected from the group consisting of a fatty alcohol having from 12 to 31 carbon atoms; a fatty ester of a glycol which has at least one free hydroxy group with a fatty acid of from 12 to 22 carbon atoms; a fatty ester of a glycerol which has at least one free hydroxy group with a fatty acid of from 12 to 22 carbon atoms; a solid ester of a fatty hydroxy acid with a lower aliphatic alcohol, the said ester having a total carbon content of 12 to 62 carbon atoms; a solid ester of a fatty polyhydric alcohol with a lower aliphatic acid, the said ester having a total carbon content of 12 to 62 carbon atoms; and a non-toxic, solid cellulose derivative represented by cellulose-R in which the R moiety is a member selected from the group consisting of an aliphatic alkyl group of from 1 to carbon atoms and an aliphatic acyl group of from 2 to 22 carbon atoms, the ratio by weight of said lipid material to said cellulosic material being from about 1:1 to about 9:1.
2. A coating material in accordance with claim 1 characterized in that the ratio by weight of said lipid ma terial to said cellulosic material is about 4: 1.
3. A coating material for medicaments to prolong the release of the medicament in the gastrointestinal tract which comprises an intimate mixture of hydrogenated castor oil and ethyl cellulose, the ratio by weight of hydrogenated castor oil to ethyl cellulose being from about 1:1 to about 9:1.
4. A coating material in accordance with claim 3 characterized in that the ratio by weight of hydrogenated castor oil to ethyl cellulose is about 4: 1.
5. A coating material for medicaments to prolong the release of the medicament in the gastrointestinal tract which comprises an intimate mixture of hydrogenated 5 characterized in that'the ratio .by weight of IZ-hydroxy- 'stearyl'alcohol to ethyl cellulose is about 4:1.
castor oil and cellulose acetate butyrate, the ratio by weight. of hydrogenated castor oil to cellulose acetate butyrate being from about 1: 1 to about 9: 1.
6. A coating material in accordance with claim 5 characterized in that the ratio by weight of hydrogenated castor oil to cellulose acetate butyrate is about 4:1.
7. A coating material for medicaments to prolong the release of the medicament in the gastrointestinal tract which comprises an intimate mixture of 12 hydroxystearyl alcohol and ethyl cellulose, the ratio by weight of IZ-hydroxystearyl alcohol to ethyl cellulose being from about 1:1 to about 9:1. v
'8, A coating material in accordance with claim 7 9. A coating material for medicaments to prolong the release of the medicament in the gastrointestinal tract which comprises an intimate mixture of l2-hydroxystearyl alcohol and cellulose acetate butyrate, the ratio by weight of IZ-hydroxystearyl alcohol to cellulose acetate butyrate being from about 1:1 to about 9:1.
10. A coating material in accordance with claim 9 characterized in that the ratio by weight of l2-hydroxystearyl alcohol to cellulose acetate butyrate is about 4:1.
11. A coating material for medicaments to prolong the release of the medicament in the gastrointestinal tract which comprises an intimate mixture of glyceryl tri-12- hydroxystearate and ethyl cellulose, the ratio by weight of glyceryl tri-lZ-hydroxystearate to ethyl cellulose being from about 1:1 to about 9:1.
12. A coating material in accordance with claim 11 characterized in that the ratio by weight of glyceryl tri- 12-hydroxystearate to ethyl cellulose is about 4: 1.
13. A pharmaceutical preparation providing a prolonged release of the contained medicament in the gastrointestinal tract which comprises a medicament protected by a coating comprising an intimate mixture of a nontoxic, solid hydroxylated lipid material selected from the group consisting of glyceryl tri-IZ-hydroxystearate, glyceryl di-12-hydroxystearate, glyceryl mono-IZ-hydroxystearate, behenyl alcohol, stearyl alcohol and 12-hydroxystearyl alcohol and a non-toxic, solid cellulose derivative selected from the group consisting of ethyl cellulose, methyl cellulose, propyl cellulose, cellulose acetate, cellulose acetate butyrate, cellulose propionate, cellulose caprate, cellulose acetate propionate and cellulose acetate stearate, the ratio by weight of said lipid material to said cellulosic material being from about 1:1 to about 9: 1.
14. A pharmaceutical preparation in accordance with claim 13 characterized in that the ratio by weight of said lipid material to said cellulosic material is about 4:1.
References Cited in the file of this patent UNITED STATES PATENTS 2,196,768 Hiatt Apr. 9, 1940 2,373,763 Kuever et al Apr. 17, 1945 2,540,979 Clymer et al. Feb. 6, 1951 2,798,024 Zapapas July 2, 1957 2,805,977 Robinson Sept. 10, 1957 2,881,085 Endicott Apr. 7, 1959 FOREIGN PATENTS 109,438 Australia Ian. 11, 1940 164,481 Australia Aug. 5, 1955 UNITED STATES PATENT OFFICE Certificate Patent- No. 2,921,883 Patented January 19, 1960 Davis R. Reese and Joseph V. Swintosky Application having been made jointly by Davis R. Reese and Joseph V. Swintosky, the inventors named in the patent above identified, and Smith Kline & French Laboratories, Philadelphia, Pennsylvania, a corporation of Pennsylvania, the assignee, for the issuance of a certificate under-the provisions of Title 35, Section 256 of the United States Code, deleting the name of the said Davis R. Reese from the patent as a joint inventor, and a showing and proof of facts satisfying the requirements of the said section having been submitted, it is this 19th day of February 1963, certified that the name of the said Davis R. Reese is hereby deleted from the said patent as a joint inventor with the said Joseph V. Swmtosky.
EDWIN L. REYNOLDS, First Assistant Uommz'ssz'oner of Patents.
5 UNITED STATES PATENT OFFICE i Certificate Patent No. 2,921,883 Patented January 19, 1960 D vis R. Reese and Joseph V. Swintosky Application having been made jointly by Davis R. Reese and Joseph V. Swintosky, the inventors named in the patent above identified, and Smith Kline & French Laboratories, Philadelphia, Pennsylvania, a corporation of Pennsylvania, the assignee, for the issuance of a certificate under-'the provisions of Title 35, Section 256 of the United States Code, deleting the name of the said Davis R. Reese from the patent as a joint inventor, and a showing and proof of facts satisfying the requirements of the said section having been submitted, it is this 19th day of February 1963, certified that the name of the said Davis R. Reese is hereby deleted from the said patent as a joint inventor with the said Joseph V. Swintosky.
[sEAL] EDWIN L. REYNOLDS, First Assistant Gammz'ssz'oner 0 Patents.
Claims (1)
1. A COATING MATERIAL FOR MEDICAMENTS TO PROLONG THE RELEASE OF THE MEDICAMENT IN THE GASTROINTESTINAL TRACT WHICH COMPRISES AN INTIMATE MIXTURE OF A NON-TOXIC, SOLID HYDROXYLATED LIPID MATERIAL SELECTED FROM THE GROUP CONSISTING OF A FATTY ALCOHOL HAVING FROM 12 TO 31 CARBON ATOMS, A FATTY ESTER OF A GLYCOL WHICH HAS AT LEAST ONE FREE HYDROXY GROYP WITH A FATTY ACID OF FROM 12 TO 22 CARBON ATOMS, A FATTY ESTER OF A GLYCEROL WHICH HAS AT LEAST ONE FREE HYDROXY GROUP WITH A FATTY ACID OF FROM 12 TO 22 CARBON ATOMS, A SOLID ESTER OF A FATTY HYDROXY ACID WITH A LOWER ALIPHATIC ALCOHOL, THE SAID ESTER HAVING A TOTAL CARBON CONTENT OF 12 TO 62 CARBON ATOMS, A SOLID ESTER OF A FATTY POLYHYDRIC ALCOHOL WITH A LOWER ALIPHATIC ACID, THE SAID ESTER HAVING A TOTAL CARBON CONTENT OF 12 TO 62 CARBON ATOMS, AND A NON-TOXIC, SOLID CELLULOSE DERIVATIVE REPRESENTED BY CELLULOSE-R IN WHICH THE R MOIETY, IS A MEMBER SELECTED FROM THE GROUP CONSISTING OF AN ALIPHATIC ALKYL GROUP OF FROM 1 TO 5 CARBON ATOMS AND AN ALIPHATIC ACYL GROUP OF FROM 2 TO 22 CARBON ATOMS, THE RATIO BY WEIGHT OF SAID LIPID MATERIAL TO SAID CELLULOSIC MATERIAL BEING FROM ABOUT 1:1 TO ABOUT 9:1.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US656750A US2921883A (en) | 1957-05-03 | 1957-05-03 | Novel coating material for medicaments |
DES58047A DE1106454B (en) | 1957-05-03 | 1958-04-29 | Coating agents for drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US656750A US2921883A (en) | 1957-05-03 | 1957-05-03 | Novel coating material for medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
US2921883A true US2921883A (en) | 1960-01-19 |
Family
ID=24634395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US656750A Expired - Lifetime US2921883A (en) | 1957-05-03 | 1957-05-03 | Novel coating material for medicaments |
Country Status (2)
Country | Link |
---|---|
US (1) | US2921883A (en) |
DE (1) | DE1106454B (en) |
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3078216A (en) * | 1961-04-11 | 1963-02-19 | American Cyanamid Co | Prolonged release oral pharmaceutical preparations |
US3096241A (en) * | 1959-07-13 | 1963-07-02 | Wallace & Tiernan Inc | Synergistic antihistamine mixture |
US3108046A (en) * | 1960-11-25 | 1963-10-22 | Smith Kline French Lab | Method of preparing high dosage sustained release tablet and product of this method |
US3119742A (en) * | 1962-12-19 | 1964-01-28 | Smith Kline French Lab | Method of preparing sustained release pharmaceutical pellets and product thereof |
US3133863A (en) * | 1961-03-10 | 1964-05-19 | Strong Cobb Arner Inc | Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums |
US3136695A (en) * | 1961-03-10 | 1964-06-09 | Strong Cobb Arner Inc | Anhydrous thixotropic gel sustained release therapeutic compositions and method of preparation |
US3146167A (en) * | 1961-10-05 | 1964-08-25 | Smith Kline French Lab | Method of preparing sustained release pellets and products thereof |
US3185625A (en) * | 1961-11-08 | 1965-05-25 | Brown Ethan Allan | Injectionable substances |
US3247065A (en) * | 1963-10-14 | 1966-04-19 | Hoffmann La Roche | Free-flowing coated ascorbic acid |
US3247066A (en) * | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
US3256153A (en) * | 1963-02-08 | 1966-06-14 | Smith Kline French Lab | Method of stabilizing wax-fat coating materials and product thereof |
US3266992A (en) * | 1962-01-25 | 1966-08-16 | Organon Nv | Tablets and method of preparing the same |
US3492397A (en) * | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US3549746A (en) * | 1967-11-02 | 1970-12-22 | Bristol Myers Co | Antibiotic composition |
US3626056A (en) * | 1967-11-02 | 1971-12-07 | Bristol Myers Co | Oral antibiotic product |
DE1492140B1 (en) * | 1964-10-20 | 1972-05-31 | Ile De France | Coating process |
US3879511A (en) * | 1972-07-03 | 1975-04-22 | Warner Lambert Co | Tasteless methenamine mandelate in a stabilized vegetable oil suspension |
US3965256A (en) * | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US4083949A (en) * | 1973-07-17 | 1978-04-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New oral form of medicament and a method for producing it |
US4096239A (en) * | 1975-04-28 | 1978-06-20 | Syntex Corporation | Inert core implant pellet |
US4138475A (en) * | 1977-06-01 | 1979-02-06 | Imperial Chemical Industries Limited | Sustained release pharmaceutical composition |
US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
US4235870A (en) * | 1971-06-03 | 1980-11-25 | Syngergistics | Slow release pharmaceutical compositions |
US4261971A (en) * | 1978-12-05 | 1981-04-14 | Aktiebolaget Hassle | Pharmaceutically preparation comprising a cardiac glycoside in combination with a polymer |
US4263273A (en) * | 1978-12-22 | 1981-04-21 | Aktiebolaget Astra | Pharmaceutical preparation comprising a cardiac glycoside with a polymer coating |
EP0032004A2 (en) * | 1979-12-19 | 1981-07-15 | Euro-Celtique S.A. | Controlled release compositions |
EP0222411A2 (en) * | 1985-11-15 | 1987-05-20 | Taisho Pharmaceutical Co. Ltd | Method of preparing sustained-release pharmaceutical preparation |
US4728512A (en) * | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US4752470A (en) * | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
US4755387A (en) * | 1985-03-21 | 1988-07-05 | The Procter & Gamble Company | Therapeutic particles |
US4794001A (en) * | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4806361A (en) * | 1984-06-04 | 1989-02-21 | Sterling Drug Inc. | Medicaments in sustained release unit dose form |
GR880100297A (en) * | 1987-05-08 | 1989-02-23 | Orion Yhtymae Oy | A new synthesis / composition |
EP0315414A1 (en) * | 1987-11-06 | 1989-05-10 | Tanabe Seiyaku Co., Ltd. | Controlled release dosage form |
US4834985A (en) * | 1986-06-05 | 1989-05-30 | Euroceltique S.A. | Controlled release pharmaceutical composition |
US4853229A (en) * | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
US4865851A (en) * | 1987-05-14 | 1989-09-12 | Glaxo Group Limited | Pharmaceutical composition comprising cefuroxime axetil |
US4904476A (en) * | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
EP0359195A2 (en) * | 1988-09-16 | 1990-03-21 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Controlled release therapeutic system for liquid pharmaceutical formulations |
US4937081A (en) * | 1988-01-14 | 1990-06-26 | Daicel Chemical Industries Ltd. | Process for producing porous, spherical particles |
US4961932A (en) * | 1987-10-26 | 1990-10-09 | Alza Corporation | Plurality of tiny pills in liquid dosage form |
US4994279A (en) * | 1988-02-03 | 1991-02-19 | Eisai Co., Ltd. | Multi-layer granule |
US5008118A (en) * | 1987-06-23 | 1991-04-16 | Nippon Oil And Fats | Method for producing organic agent coated with powders of coating agent |
US5030454A (en) * | 1987-10-26 | 1991-07-09 | Alza Corporation | Method for delivering drug in tiny pills in liquid carrier |
US5213811A (en) * | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
US5296236A (en) * | 1988-09-16 | 1994-03-22 | Recordati S.A., Chemical And Pharmaceutical Company | Controlled release therapeutic system for a liquid pharmaceutical formulations |
US5328697A (en) * | 1992-02-10 | 1994-07-12 | Mallinckrodt Veterinary, Inc. | Compositions and processes for the sustained release of drugs |
US5348747A (en) * | 1992-03-05 | 1994-09-20 | American Home Products Corporation | Pharmaceutical coating sugars |
US6056992A (en) * | 1988-06-02 | 2000-05-02 | Campbell Soup Company | Encapsulated additives |
EP1101490A1 (en) * | 1998-07-28 | 2001-05-23 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
US20030099707A1 (en) * | 2000-10-13 | 2003-05-29 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US20040052842A1 (en) * | 2000-02-24 | 2004-03-18 | Rudnic Edward M. | Antibiotic product, use and formulation thereof |
US20040096500A1 (en) * | 1991-11-27 | 2004-05-20 | Benjamin Oshlack | Controlled release oxycodone compositions |
US20040170680A1 (en) * | 2001-05-02 | 2004-09-02 | Benjamin Oshlack | Once-a-day oxycodone formulations |
US20060099263A1 (en) * | 1993-05-27 | 2006-05-11 | Edgren David E | Antidepressant dosage form |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
US20080055036A1 (en) * | 2006-08-29 | 2008-03-06 | International Business Machines Corporation | Electrical component tuned by conductive layer deletion |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
US20090263479A1 (en) * | 2008-04-22 | 2009-10-22 | Solvay Phamaceuticals Gmbh | Formulations for poorly permeable active pharmaceutical ingredients |
US20110104214A1 (en) * | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1293952B (en) * | 1963-08-07 | 1969-04-30 | Diwag Chemische Fabriken Gmbh | Process for the production of pharmaceutical preparations for oral use with protracted release of active substances |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2196768A (en) * | 1938-03-11 | 1940-04-09 | Eastman Kodak Co | Enteric coating |
US2373763A (en) * | 1941-11-24 | 1945-04-17 | State Of Iowa | Enteric coating |
US2540979A (en) * | 1948-04-24 | 1951-02-06 | Smith Kline French Lab | Enteric coating |
US2798024A (en) * | 1954-06-02 | 1957-07-02 | Lilly Co Eli | Composite enteric tablet of erythromycin and sulfonamides |
US2805977A (en) * | 1955-01-04 | 1957-09-10 | Smith Kline French Lab | Sustained release pharmaceutical preparation |
US2881085A (en) * | 1953-11-09 | 1959-04-07 | Abbott Lab | Thin film coating for tablets and the like |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT125943B (en) * | 1930-11-18 | 1931-12-28 | Karl Dr Glaessner | Process for the production of coatings or casings for drugs, which should only take effect in the intestine. |
-
1957
- 1957-05-03 US US656750A patent/US2921883A/en not_active Expired - Lifetime
-
1958
- 1958-04-29 DE DES58047A patent/DE1106454B/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2196768A (en) * | 1938-03-11 | 1940-04-09 | Eastman Kodak Co | Enteric coating |
US2373763A (en) * | 1941-11-24 | 1945-04-17 | State Of Iowa | Enteric coating |
US2540979A (en) * | 1948-04-24 | 1951-02-06 | Smith Kline French Lab | Enteric coating |
US2881085A (en) * | 1953-11-09 | 1959-04-07 | Abbott Lab | Thin film coating for tablets and the like |
US2798024A (en) * | 1954-06-02 | 1957-07-02 | Lilly Co Eli | Composite enteric tablet of erythromycin and sulfonamides |
US2805977A (en) * | 1955-01-04 | 1957-09-10 | Smith Kline French Lab | Sustained release pharmaceutical preparation |
Cited By (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3096241A (en) * | 1959-07-13 | 1963-07-02 | Wallace & Tiernan Inc | Synergistic antihistamine mixture |
US3108046A (en) * | 1960-11-25 | 1963-10-22 | Smith Kline French Lab | Method of preparing high dosage sustained release tablet and product of this method |
US3133863A (en) * | 1961-03-10 | 1964-05-19 | Strong Cobb Arner Inc | Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums |
US3136695A (en) * | 1961-03-10 | 1964-06-09 | Strong Cobb Arner Inc | Anhydrous thixotropic gel sustained release therapeutic compositions and method of preparation |
US3078216A (en) * | 1961-04-11 | 1963-02-19 | American Cyanamid Co | Prolonged release oral pharmaceutical preparations |
US3146167A (en) * | 1961-10-05 | 1964-08-25 | Smith Kline French Lab | Method of preparing sustained release pellets and products thereof |
US3185625A (en) * | 1961-11-08 | 1965-05-25 | Brown Ethan Allan | Injectionable substances |
US3266992A (en) * | 1962-01-25 | 1966-08-16 | Organon Nv | Tablets and method of preparing the same |
US3247066A (en) * | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
US3119742A (en) * | 1962-12-19 | 1964-01-28 | Smith Kline French Lab | Method of preparing sustained release pharmaceutical pellets and product thereof |
US3256153A (en) * | 1963-02-08 | 1966-06-14 | Smith Kline French Lab | Method of stabilizing wax-fat coating materials and product thereof |
US3247065A (en) * | 1963-10-14 | 1966-04-19 | Hoffmann La Roche | Free-flowing coated ascorbic acid |
DE1492140B1 (en) * | 1964-10-20 | 1972-05-31 | Ile De France | Coating process |
US3492397A (en) * | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US3549746A (en) * | 1967-11-02 | 1970-12-22 | Bristol Myers Co | Antibiotic composition |
US3626056A (en) * | 1967-11-02 | 1971-12-07 | Bristol Myers Co | Oral antibiotic product |
US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4235870A (en) * | 1971-06-03 | 1980-11-25 | Syngergistics | Slow release pharmaceutical compositions |
US3965256A (en) * | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3879511A (en) * | 1972-07-03 | 1975-04-22 | Warner Lambert Co | Tasteless methenamine mandelate in a stabilized vegetable oil suspension |
US4083949A (en) * | 1973-07-17 | 1978-04-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New oral form of medicament and a method for producing it |
US4096239A (en) * | 1975-04-28 | 1978-06-20 | Syntex Corporation | Inert core implant pellet |
US4138475A (en) * | 1977-06-01 | 1979-02-06 | Imperial Chemical Industries Limited | Sustained release pharmaceutical composition |
US4261971A (en) * | 1978-12-05 | 1981-04-14 | Aktiebolaget Hassle | Pharmaceutically preparation comprising a cardiac glycoside in combination with a polymer |
US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
US4263273A (en) * | 1978-12-22 | 1981-04-21 | Aktiebolaget Astra | Pharmaceutical preparation comprising a cardiac glycoside with a polymer coating |
EP0032004A2 (en) * | 1979-12-19 | 1981-07-15 | Euro-Celtique S.A. | Controlled release compositions |
FR2474507A1 (en) * | 1979-12-19 | 1981-07-31 | Euro Celtique Sa | PROGRESSIVE RELEASE COMPOSITIONS OF THE ACTIVE SUBSTANCE AND COMPLEXES FOR THEIR PREPARATION |
EP0032004A3 (en) * | 1979-12-19 | 1982-07-14 | Euro-Celtique S.A. | Controlled release compositions |
US4806361A (en) * | 1984-06-04 | 1989-02-21 | Sterling Drug Inc. | Medicaments in sustained release unit dose form |
US4755387A (en) * | 1985-03-21 | 1988-07-05 | The Procter & Gamble Company | Therapeutic particles |
US4728512A (en) * | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
EP0222411A2 (en) * | 1985-11-15 | 1987-05-20 | Taisho Pharmaceutical Co. Ltd | Method of preparing sustained-release pharmaceutical preparation |
EP0222411A3 (en) * | 1985-11-15 | 1987-11-25 | Taisho Pharmaceutical Co. Ltd | Method of preparing sustained-release pharmaceutical preparation |
US4853249A (en) * | 1985-11-15 | 1989-08-01 | Taisho Pharmaceutical Co., Ltd. | Method of preparing sustained-release pharmaceutical/preparation |
US4794001A (en) * | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4904476A (en) * | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4834985A (en) * | 1986-06-05 | 1989-05-30 | Euroceltique S.A. | Controlled release pharmaceutical composition |
US4752470A (en) * | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
GR880100297A (en) * | 1987-05-08 | 1989-02-23 | Orion Yhtymae Oy | A new synthesis / composition |
BE1000785A3 (en) * | 1987-05-08 | 1989-04-04 | Orion Yhtymae Oy | Composition administered drug form of tablets, powder or liquid. |
AU610161B2 (en) * | 1987-05-08 | 1991-05-16 | Orion-Yhtyma Oy | Layered coatings for pharmaceutical granules |
US4935247A (en) * | 1987-05-08 | 1990-06-19 | Orion-Yhtyma Oy | Composition for the oral administration of pharmaceuticals |
FR2630912A1 (en) * | 1987-05-08 | 1989-11-10 | Orion Yhtymae Oy | COMPOSITION FOR ADMINISTERING A MEDICAMENT IN THE FORM OF GELULES, POWDER OR LIQUID |
US4865851A (en) * | 1987-05-14 | 1989-09-12 | Glaxo Group Limited | Pharmaceutical composition comprising cefuroxime axetil |
US5008118A (en) * | 1987-06-23 | 1991-04-16 | Nippon Oil And Fats | Method for producing organic agent coated with powders of coating agent |
US4961932A (en) * | 1987-10-26 | 1990-10-09 | Alza Corporation | Plurality of tiny pills in liquid dosage form |
US4853229A (en) * | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
US5030454A (en) * | 1987-10-26 | 1991-07-09 | Alza Corporation | Method for delivering drug in tiny pills in liquid carrier |
US4963365A (en) * | 1987-11-06 | 1990-10-16 | Tanabe Seiyaku Co., Ltd. | Controlled release dosage form |
EP0315414A1 (en) * | 1987-11-06 | 1989-05-10 | Tanabe Seiyaku Co., Ltd. | Controlled release dosage form |
FR2622799A1 (en) * | 1987-11-06 | 1989-05-12 | Tanabe Seiyaku Co | CONTROLLED RELEASE PHARMACEUTICAL DOSAGE FORM AND PROCESS FOR ITS PREPARATION |
US4937081A (en) * | 1988-01-14 | 1990-06-26 | Daicel Chemical Industries Ltd. | Process for producing porous, spherical particles |
US4994279A (en) * | 1988-02-03 | 1991-02-19 | Eisai Co., Ltd. | Multi-layer granule |
US6056992A (en) * | 1988-06-02 | 2000-05-02 | Campbell Soup Company | Encapsulated additives |
EP0359195A2 (en) * | 1988-09-16 | 1990-03-21 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Controlled release therapeutic system for liquid pharmaceutical formulations |
US5296236A (en) * | 1988-09-16 | 1994-03-22 | Recordati S.A., Chemical And Pharmaceutical Company | Controlled release therapeutic system for a liquid pharmaceutical formulations |
US5405619A (en) * | 1988-09-16 | 1995-04-11 | Recordati S.A., Chemical And Pharmaceutical Company | Controlled release therapeutic system for liquid pharmaceutical formulations |
US5510119A (en) * | 1988-09-16 | 1996-04-23 | Recordati S.A., Chemical And Pharmaceuticl Company | Controlled release therapeutic system for liquid pharmaceutical formulations |
EP0359195A3 (en) * | 1988-09-16 | 1991-04-24 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Controlled release therapeutic system for liquid pharmaceutical formulations |
US5213811A (en) * | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
US20060057210A1 (en) * | 1991-11-27 | 2006-03-16 | Purdue Pharma L.P. | Controlled release oxycodone compositions |
US20040096500A1 (en) * | 1991-11-27 | 2004-05-20 | Benjamin Oshlack | Controlled release oxycodone compositions |
US5328697A (en) * | 1992-02-10 | 1994-07-12 | Mallinckrodt Veterinary, Inc. | Compositions and processes for the sustained release of drugs |
US5348747A (en) * | 1992-03-05 | 1994-09-20 | American Home Products Corporation | Pharmaceutical coating sugars |
US20100092570A1 (en) * | 1992-11-25 | 2010-04-15 | Purdue Pharma L.P. | Controlled release oxycodone compositions |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
US20060099263A1 (en) * | 1993-05-27 | 2006-05-11 | Edgren David E | Antidepressant dosage form |
US20100034876A1 (en) * | 1993-06-18 | 2010-02-11 | Purdue Pharma L.P. | Controlled release oxycodone compositions |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
EP1101490A4 (en) * | 1998-07-28 | 2002-04-03 | Tanabe Seiyaku Co | Preparation capable of releasing drug at target site in intestine |
EP1101490A1 (en) * | 1998-07-28 | 2001-05-23 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
US20040052842A1 (en) * | 2000-02-24 | 2004-03-18 | Rudnic Edward M. | Antibiotic product, use and formulation thereof |
US8889187B2 (en) | 2000-02-24 | 2014-11-18 | Shionogi Inc. | Once a day amoxicillin product comprising immediate and delayed release dosage forms |
US20030099707A1 (en) * | 2000-10-13 | 2003-05-29 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US20110065718A1 (en) * | 2000-10-13 | 2011-03-17 | Victory Pharma, Inc. | Antifungal Product, Use and Formulation Thereof |
US8303988B2 (en) | 2000-10-13 | 2012-11-06 | Shionogi Inc. | Antifungal once-a-day product, use and formulation thereof |
US20040170680A1 (en) * | 2001-05-02 | 2004-09-02 | Benjamin Oshlack | Once-a-day oxycodone formulations |
US7846476B2 (en) | 2001-05-02 | 2010-12-07 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
US9655893B2 (en) | 2001-05-02 | 2017-05-23 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
US9655894B2 (en) | 2001-05-02 | 2017-05-23 | Purdue Pharma L.P. | Once-A day oxycodone formulations |
US9750736B2 (en) | 2001-05-02 | 2017-09-05 | Purdue Pharma L.P. | Oxycodone formulations |
US10660886B2 (en) | 2001-05-02 | 2020-05-26 | Purdue Pharma L.P. | Oxycodone formulations |
US20110104214A1 (en) * | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
US20080055036A1 (en) * | 2006-08-29 | 2008-03-06 | International Business Machines Corporation | Electrical component tuned by conductive layer deletion |
US20090263479A1 (en) * | 2008-04-22 | 2009-10-22 | Solvay Phamaceuticals Gmbh | Formulations for poorly permeable active pharmaceutical ingredients |
Also Published As
Publication number | Publication date |
---|---|
DE1106454B (en) | 1961-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US2921883A (en) | Novel coating material for medicaments | |
US3432593A (en) | Delayed and sustained release type pharmaceutical preparation | |
US2805977A (en) | Sustained release pharmaceutical preparation | |
US3119742A (en) | Method of preparing sustained release pharmaceutical pellets and product thereof | |
KR910004577B1 (en) | Process for preparing multilayer granule | |
US3080294A (en) | Sustained release type of pharmaceutical vehicles | |
US3138525A (en) | Castor wax-amprotropine-resin compositions | |
EP0431877B1 (en) | Cimetidine pharmaceutical compositions | |
US4380534A (en) | Solid drug preparations | |
US2738303A (en) | Sympathomimetic preparation | |
KR950009097B1 (en) | Pharmaceufical composition containing cefuroxime axetil | |
US3670065A (en) | Process for producing dosage units of a type resembling tablets | |
EP0103991A2 (en) | Analgesic capsule | |
EP0035780B1 (en) | Coating compositions for enterosoluble solid dosage forms | |
US3939259A (en) | Coating composition and therapeutic preparation incorporating same | |
US3328256A (en) | Spherical beads and their production | |
US3256111A (en) | Method for coating tablets | |
US2656298A (en) | Therapeutic product | |
JP3349535B2 (en) | Method for producing spherical granules | |
WO1991019486A1 (en) | Stable aqueous drug suspensions | |
US5026709A (en) | Method for the preparation of a theophylline sustained release pharmaceutical composition and the composition prepared thereby | |
US3044938A (en) | Sustained action pharmaceutical tablets | |
JPH0443052B2 (en) | ||
EP0298666A2 (en) | Spray dried ibuprofen compositions | |
JPS60193913A (en) | Sustained release agent and its preparation |